Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 16/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164817 | 0.89 | NPC1L1 (0.64) | NPC1L1CYP3A4TSHRDDR1 | |
| SCHEMBL5553240 | 0.88 | NPC1L1 (0.58) | NPC1L1CYP3A4TSHRUSP2HSD17B10 | |
| SCHEMBL5559600 | 0.87 | CYP3A4 (0.56) | NPC1L1CYP3A4TSHRUSP2HSD17B10 | |
| SCHEMBL5553404 | 0.86 | CYP3A4 (0.58) | NPC1L1CYP3A4TSHRUSP2HSD17B10 | |
| SCHEMBL5558479 | 0.86 | CYP3A4 (0.55) | NPC1L1CYP3A4TSHRUSP2HSD17B10 | |
| SCHEMBL5557593 | 0.86 | NPC1L1 (0.58) | NPC1L1CYP3A4TSHRDDR1 | |
| SCHEMBL5558408 | 0.85 | DDR1 (0.54) | NPC1L1CYP3A4TSHRUSP2HSD17B10 | |
| SCHEMBL5557700 | 0.85 | DDR1 (0.53) | NPC1L1CYP3A4TSHRUSP2HSD17B10 | |
| SCHEMBL5558533 | 0.85 | DDR1 (0.64) | NPC1L1CYP3A4TSHRDDR1 | |
| SCHEMBL5557433 | 0.85 | NPC1L1 (0.56) | NPC1L1CYP3A4TSHRUSP2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6482829-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-11-19 | — | — | US | claimed |
| US-20020006932-A1 | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-17 | — | — | US | claimed |
| EP-1292596-B1 | 1,3,8-TRIAZA-SPIRO¬4,5 DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-6482829-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020006932-A1 | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006932-A1 | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor | TACR1, TACR2, NPR1 | NPC1L1 2001/4885CYP3A4 3223/4885TSHR 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.